Tim Pardee
Co-Leader · Wake Forest University Baptist Medical Center
Credentials: · · · · · ·
History
Research
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
New England Journal of Medicine · 2019 · 1,078 citations
Blood · 2013 · 361 citations
Mouse models of human AML accurately predict chemotherapy response
Genes & Development · 2009 · 241 citations
23 papers
19 papers · 2 as a resident
16 papers
- EL
11 papers
10 papers
10 papers
8 papers
6 papers
Grants
- 2020–2026
Translational Oncology Training Program
National Cancer Institute · T32
PI · $1.4M · Wake Forest University Health Sciences
- 2024–2026
Developing Acute Myeloid Leukemia Models with Diverse Ancestral Origins
National Cancer Institute · R21
Contact PI · $390.8K · Wake Forest University Health Sciences
- 2018–2024
Chromatin Mobility in Response to DNA Damage
National Cancer Institute · U01
Contact PI · $1.2M · Wake Forest University Health Sciences
- 2016–2022
Determining the Role of Metabolism in Resistance in Acute Myeloid Leukemia
National Cancer Institute · R01
Contact PI · $1.8M · Wake Forest University Health Sciences
Clinical trials
- 2026–2029
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Principal investigator · Recruiting · Phase 2
Timothy Pardee
- 2019–2027
Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity
Principal investigator · Active not recruiting
Wake Forest University Health Sciences
- 2018–2027
Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients
Principal investigator · Active not recruiting · Phase 2
Wake Forest University Health Sciences
- 2017–2022
Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia
Principal investigator · Completed
Wake Forest University Health Sciences